The success of copyright’s blockbuster initially fueled a surge for pharma, nevertheless recent developments present a uncertain scenario for investors. Off-patent alternatives are eroding profits, and ongoing patent challenges add additional risk to the landscape. While specific companies may still benefit from complementary products, the broad… Read More